Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Automated Radiation Target Contouring and Treatment Planning Via RATA: A Multi-Center RCT

2 november 2026 bijgewerkt door: zhaoxiaohui

Automated Target Volume Contouring and Intelligent Treatment Planning Based on a Multi-Agent Collaborative Radiotherapy Large Model (RATA): A Multi-Center Validation and Prospective Randomized Controlled Trial

Radiotherapy, a cornerstone of comprehensive cancer treatment, relies heavily on clinician expertise for target volume contouring and treatment planning. Consequently, clinical practice is often constrained by procedural bottlenecks, inter-observer variability, and prolonged iterative feedback cycles. Although current artificial intelligence (AI) models have demonstrated progress in automated contouring, key limitations persist, including insufficient integration of multimodal clinical text, a lack of closed-loop dosimetric feedback, and limited generalizability across complex cancer types.

This study aims to develop and validate RATA (Radiotherapy Treatment Multi-Agent Assistant), a novel large model system powered by a collaborative multi-agent architecture. Driven by Large Language Model (LLM) decision engines, RATA processes pathological imaging, electronic health records (EHR), and multimodal medical data to construct a end-to-end, fully automated closed-loop pipeline encompassing "target contouring, plan design, dosimetric evaluation, and reflective refinement." Innovatively breaking through traditional unidirectional radiotherapy workflows, the system establishes a dosimetric feedback-driven adaptive iteration mechanism, leveraging dose distribution outcomes to guide multi-agent dynamic fine-tuning of target volumes, thereby mimicking the collaborative clinical logic between senior radiation oncologists and medical physicists.

For validation, this study adopts a multi-center, three-stage clinical validation framework-comprising multi-center retrospective validation, human-AI collaborative efficacy assessment, and a prospective randomized controlled trial (RCT)-to comprehensively evaluate the system's performance in improving contouring precision, mitigating experience-dependent disparities across clinician seniority, and reducing total workflow processing time. Implementation of the RATA platform holds potential to eliminate redundant operational steps, enabling a minute-level "scan-to-treat" response. Furthermore, its natural language interaction interface optimizes human-AI collaboration and substantially reduces clinical workload. Overall, this study not only establishes a standardized, intelligent assistance paradigm for precision radiation oncology but also provides essential evidence-based support and technological foundations for the clinical translation of multimodal AI in complex cancer management.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

62

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contact:
        • Hoofdonderzoeker:
          • Xiaohui Zhao, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Pathologically confirmed malignant neoplasm requiring definitive or adjuvant radiotherapy.
  • Availability of verified pathology report.
  • Availability of baseline imaging examinations and diagnostic reports.
  • Availability of standardized and complete clinical electronic health records.

Exclusion Criteria:

  • Incomplete clinical, imaging, or follow-up data.
  • Presence of multiple primary malignancies.
  • Patients scheduled for salvage or palliative radiotherapy.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Onderzoek naar gezondheidsdiensten
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: RATA-Assisted Workflow Arm

Patients in this arm receive radiotherapy using the RATA-assisted "scan-to-treat" model. Patients remain in position on the couch while the Multi-Agent Collaborative Radiotherapy Large Model (RATA) executes target volume contouring, treatment planning, dosimetric evaluation, and reflective refinement in a closed-loop automated workflow, enabling rapid delivery of the first fraction.

An AI-driven multi-agent platform utilizing large language model decision engines to automatically perform target volume contouring, dosimetric plan generation, evaluation, and adaptive refinement for cancer radiotherapy.

Actieve vergelijker: Standard Offline Workflow Arm

Patients in this arm follow the traditional offline clinical workflow. After initial simulation CT scanning, patients leave the treatment room while radiation oncologists and medical physicists manually perform target contouring and treatment planning according to standard practice. Patients return to the clinic at a later scheduled time for their first radiation fraction.

Conventional offline radiation therapy planning workflow, where target volume contouring and treatment planning are manually performed by radiation oncologists and medical physicists according to routine institutional protocols.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total Closed-Loop Workflow Duration
Tijdsspanne: At the time of simulation and treatment planning for each participant (up to 1 day)

Total time (in minutes) required for the complete end-to-end radiotherapy planning closed-loop workflow, measured from initial CT simulation scan completion to final clinical treatment plan approval and readiness for first fraction delivery.

At the time of simulation and treatment planning for each participant (up to 1 day)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Clinical Acceptance Rate of Treatment Plans
Tijdsspanne: At plan evaluation prior to treatment delivery (up to 1 day)

Percentage of treatment plans rated as clinically acceptable (score ≥3 on a 5-point Likert scale) by senior radiation oncologists without substantial manual re-planning.

At plan evaluation prior to treatment delivery (up to 1 day)
Planning Time and Workload Reduction Rate
Tijdsspanne: At plan evaluation prior to treatment delivery (up to 1 day)

Total clinician active manual intervention time (contour editing and plan optimization duration in minutes) and percentage of labor time saved compared to the standard manual workflow.

At plan evaluation prior to treatment delivery (up to 1 day)
Contouring Accuracy Metrics and Dosimetric Parameters
Tijdsspanne: At plan evaluation prior to treatment delivery (up to 1 day)

Geometric similarity metrics including Dice Similarity Coefficient (DSC), 95% Hausdorff Distance (HD95), and Average Surface Distance (ASD); dosimetric indicators including Target Coverage (V95%), Conformity Index (CI), Homogeneity Index (HI), and Organs-at-Risk (OAR) dose constraints.

At plan evaluation prior to treatment delivery (up to 1 day)
First Setup Verification Pass Rate
Tijdsspanne: At the first fraction of radiotherapy delivery (Day 1 of treatment)

Proportion of participants passing the initial positional setup and position verification check (e.g., CBCT/IGRT alignment) prior to the first fraction delivery on the treatment couch.

At the first fraction of radiotherapy delivery (Day 1 of treatment)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

9 november 2026

Primaire voltooiing (Geschat)

1 februari 2029

Studie voltooiing (Geschat)

28 februari 2029

Studieregistratiedata

Eerst ingediend

2 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

2 november 2026

Eerst geplaatst (Werkelijk)

6 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • SYSKY-2026-406-03

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren